Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease

European Journal of Neuroscience

Volumn 44, Issue 12, 2016, Pages 3056-3066

  Jackson, Rosemary J ^a   Rudinskiy, Nikita ^b   Herrmann, Abigail G ^a   Croft, Shaun ^a   Kim, JeeSoo Monica ^a   Petrova, Veselina ^a   Ramos Rodriguez, Juan Jose ^c   Pitstick, Rose ^d   Wegmann, Susanne ^b   Garcia Alloza, Monica ^c   Carlson, George A ^d   Hyman, Bradley T ^b   Spires Jones, Tara L ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CÁDIZ   (Spain)

^d MCLAUGHLIN RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer; amyloid beta; plaque; synapse; tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; TAU PROTEIN; THIOFLAVINE; AMYLOID PRECURSOR PROTEIN; MAPT PROTEIN, HUMAN; PRESENILIN 1; PRESENILIN 1, MOUSE;

ALZHEIMER DISEASE; AMINO ACID BRAIN LEVEL; AMYLOID PLAQUE; AMYLOID PLAQUE SIZE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLIOSIS; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEURITE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MISFOLDING; SYNAPSE; SYNAPSE LOSS; TRANSGENIC MOUSE; UPREGULATION; WILD TYPE; ANIMAL; ASTROCYTE; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; NERVE CELL; PATHOLOGY; PHOSPHORYLATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ASTROCYTES; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; NEURONS; PHOSPHORYLATION; PLAQUE, AMYLOID; PRESENILIN-1; SYNAPSES; TAU PROTEINS;

EID: 85001839733     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/ejn.13442     Document Type: Article

References (49)

1. Bilousova, T., Miller, C.A., Poon, W.W., Vinters, H.V., Corrada, M., Kawas, C., Hayden, E.Y., Teplow, D.B. et al. (2016) Synaptic amyloid-β oligomers precede p-Tau and differentiate high pathology control cases. Am. J. Pathol., 186, 185–198.
2. Castillo-Carranza, D.L., Guerrero-Munoz, M.J., Sengupta, U., Hernandez, C., Barrett, A.D., Dineley, K. & Kayed, R. (2015) Tau immunotherapy modulates both pathological tau and upstream amyloid pathology in an Alzheimer's disease mouse model. J. Neurosci., 35, 4857–4868.
3. Crimins, J.L., Pooler, A., Polydoro, M., Luebke, J.I. & Spires-Jones, T.L. (2013) The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Ageing Res. Rev., 12, 757–763.
4. DeKosky, S.T. & Scheff, S.W. (1990) Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol., 27, 457–464.
5. Duyckaerts, C., Delatour, B. & Potier, M.C. (2009) Classification and basic pathology of Alzheimer disease. Acta Neuropathol., 118, 5–36.
6. Garcia-Alloza, M., Dodwell, S.A., Meyer-Luehmann, M., Hyman, B.T. & Bacskai, B.J. (2006a) Plaque-derived oxidative stress mediates distorted neurite trajectories in the Alzheimer mouse model. J. Neuropath. Exp. Neur., 65, 1082–1089.
7. Garcia-Alloza, M., Robbins, E.M., Zhang-Nunes, S.X., Purcell, S.M., Betensky, R.A., Raju, S., Prada, C., Greenberg, S.M. et al. (2006b) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol. Dis., 24, 516–524.
8. Gomez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J.H., Petersen, R.C., Parisi, J.E. & Hyman, B.T. (1997) Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol., 41, 17–24.
9. Hardy, J.A. & Higgins, G.A. (1992) Alzheimer's disease: the amyloid cascade hypothesis. Science, 256, 184–185.
10. Hardy, J. & Selkoe, D.J. (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297, 353–356.
11. Hoover, B.R., Reed, M.N., Su, J., Penrod, R.D., Kotilinek, L.A., Grant, M.K., Pitstick, R., Carlson, G.A. et al. (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron, 68, 1067–1081.
12. Hutton, M. (2000) Molecular genetics of chromosome 17 tauopathies. Ann. NY. Acad. Sci., 920, 63–73.
13. Ingelsson, M., Fukumoto, H., Newell, K.L., Growdon, J.H., Hedley-Whyte, E.T., Frosch, M.P., Albert, M.S., Hyman, B.T. et al. (2004) Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology, 62, 925–931.
14. Jankowsky, J.L., Fadale, D.J., Anderson, J., Xu, G.M., Gonzales, V., Jenkins, N.A., Copeland, N.G., Lee, M.K. et al. (2004) Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet., 13, 159–170.
15. Kay, K.R., Smith, C., Wright, A.K., Serrano-Pozo, A., Pooler, A.M., Koffie, R., Bastin, M.E., Bak, T.H. et al. (2013) Studying synapses in human brain with array tomography and electron microscopy. Nat. Protoc., 8, 1366–1380.
16. Koffie, R.M., Meyer-Luehmann, M., Hashimoto, T., Adams, K.W., Mielke, M.L., Garcia-Alloza, M., Micheva, K.D., Smith, S.J. et al. (2009) Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. USA, 106, 4012–4017.
17. Koffie, R.M., Hashimoto, T., Tai, H.C., Kay, K.R., Serrano-Pozo, A., Joyner, D., Hou, S., Kopeikina, K.J. et al. (2012) Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. Brain, 135, 2155–2168.
18. Kopeikina, K.J., Carlson, G.A., Pitstick, R., Ludvigson, A.E., Peters, A., Luebke, J.I., Koffie, R.M., Frosch, M.P. et al. (2011) Tau accumulation causes mitochondrial distribution deficits in neurons in a mouse model of tauopathy and in human Alzheimer's disease brain. Am. J. Pathol., 179, 2071–2082.
19. Lasagna-Reeves, C.A., Castillo-Carranza, D.L., Sengupta, U., Clos, A.L., Jackson, G.R. & Kayed, R. (2011) Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol. Neurodegener., 6, 39.
20. McLellan, M.E., Kajdasz, S.T., Hyman, B.T. & Bacskai, B.J. (2003) In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy. J. Neurosci., 23, 2212–2217.
21. Menkes-Caspi, N., Yamin, H.G., Kellner, V., Spires-Jones, T.L., Cohen, D. & Stern, E.A. (2015) Pathological tau disrupts ongoing network activity. Neuron, 85, 959–966.
22. Micheva, K.D. & Smith, S.J. (2007) Array tomography: a new tool for imaging the molecular architecture and ultrastructure of neural circuits. Neuron, 55, 25–36.
23. Oddo, S., Caccamo, A., Shepherd, J.D., Murphy, M.P., Golde, T.E., Kayed, R., Metherate, R., Mattson, M.P. et al. (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron, 39, 409–421.
24. Oddo, S., Billings, L., Kesslak, J.P., Cribbs, D.H. & LaFerla, F.M. (2004) Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron, 43, 321–332.
25. Oddo, S., Vasilevko, V., Caccamo, A., Kitazawa, M., Cribbs, D.H. & LaFerla, F.M. (2006) Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem., 281, 39413–39423.
26. Perez-Nievas, B.G., Stein, T.D., Tai, H.C., Dols-Icardo, O., Scotton, T.C., Barroeta-Espar, I., Fernandez-Carballo, L., de Munain, E.L. et al. (2013) Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology. Brain, 136, 2510–2526.
27. Pooler, A.M., Polydoro, M., Maury, E.A., Nicholls, S.B., Reddy, S.M., Wegmann, S., William, C., Saqran, L. et al. (2015) Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer's disease. Acta. Neuropathol. Commun., 3, 14.
28. Ramos-Rodriguez, J.J., Infante-Garcia, C., Galindo-Gonzalez, L., Garcia-Molina, Y., Lechuga-Sancho, A. & Garcia-Alloza, M. (2016) Increased spontaneous central bleeding and cognition impairment in APP/PS1 mice with poorly controlled diabetes mellitus. Mol. Neurobiol., 53, 2685–2697.
29. Roberson, E.D., Scearce-Levie, K., Palop, J.J., Yan, F., Cheng, I.H., Wu, T., Gerstein, H., Yu, G.Q. et al. (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science, 316, 750–754.
30. Roberson, E.D., Halabisky, B., Yoo, J.W., Yao, J., Chin, J., Yan, F., Wu, T., Hamto, P. et al. (2011) Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J. Neurosci., 31, 700–711.
31. Rocher, A.B., Crimins, J.L., Amatrudo, J.M., Kinson, M.S., Todd-Brown, M.A., Lewis, J. & Luebke, J.I. (2010) Structural and functional changes in tau mutant mice neurons are not linked to the presence of NFTs. Exp. Neurol., 223, 385–393.
32. Rupp, N.J., Wegenast-Braun, B.M., Radde, R., Calhoun, M.E. & Jucker, M. (2011) Early onset amyloid lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic mice. Neurobiol. Aging, 32, 2324 e2321–2326.
33. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C. et al. (2012) Fiji: an open-source platform for biological-image analysis. Nat. Methods, 9, 676–682.
34. Shankar, G.M., Li, S., Mehta, T.H., Garcia-Munoz, A., Shepardson, N.E., Smith, I., Brett, F.M., Farrell, M.A. et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med., 14, 837–842.
35. Shipton, O.A., Leitz, J.R., Dworzak, J., Acton, C.E., Tunbridge, E.M., Denk, F., Dawson, H.N., Vitek, M.P. et al. (2011) Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation. J. Neurosci., 31, 1688–1692.
36. Small, S.A. & Duff, K. (2008) Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron, 60, 534–542.
37. Spires, T.L., Meyer-Luehmann, M., Stern, E.A., McLean, P.J., Skoch, J., Nguyen, P.T., Bacskai, B.J. & Hyman, B.T. (2005) Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci., 25, 7278–7287.
38. Spires-Jones, T.L. & Hyman, B.T. (2014) The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron, 82, 756–771.
39. Tai, H.C., Serrano-Pozo, A., Hashimoto, T., Frosch, M.P., Spires-Jones, T.L. & Hyman, B.T. (2012) The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system. Am. J. Pathol., 181, 1426–1435.
40. Tanzi, R.E. (2012) The genetics of Alzheimer disease. Cold Spring Harb. Perspect Med., 2, a006296. doi: 10.1101/cshperspect.a006296. [Epub ahead of print].
41. Terry, R.D., Masliah, E., Salmon, D.P., Butters, N., DeTeresa, R., Hill, R., Hansen, L.A. & Katzman, R. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol., 30, 572–580.
42. Thevenaz, P., Ruttimann, U.E. & Unser, M. (1998) A pyramid approach to subpixel registration based on intensity. IEEE T. Image Process., 7, 27–41.
43. Umeda, T., Maekawa, S., Kimura, T., Takashima, A., Tomiyama, T. & Mori, H. (2014) Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice. Acta Neuropathol., 127, 685–698.
44. Vossel, K.A., Xu, J.C., Fomenko, V., Miyamoto, T., Suberbielle, E., Knox, J.A., Ho, K., Kim, D.H. et al. (2015) Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β. J. Cell Biol., 209, 419–433.
45. Walls, K.C., Ager, R.R., Vasilevko, V., Cheng, D., Medeiros, R. & LaFerla, F.M. (2014) p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice. Neurosci. Lett., 575, 96–100.
46. Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J. & Selkoe, D.J. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 416, 535–539.
47. Wegmann, S., Maury, E.A., Kirk, M.J., Saqran, L., Roe, A., DeVos, S.L., Nicholls, S., Fan, Z. et al. (2015) Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. EMBO J., 34, 3028–3041.
48. Wu, H.Y., Hudry, E., Hashimoto, T., Kuchibhotla, K., Rozkalne, A., Fan, Z., Spires-Jones, T., Xie, H. et al. (2010) Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J. Neurosci., 30, 2636–2649.
49. Yang, T., O'Malley, T.T., Kanmert, D., Jerecic, J., Zieske, L.R., Zetterberg, H., Hyman, B.T., Walsh, D.M. et al. (2015) A highly sensitive novel immunoassay specifically detects low levels of soluble Abeta oligomers in human cerebrospinal fluid. Alzheimers Res. Ther., 7, 14.